← Back to Search

Mesenchymal Stem Cell

Mesenchymal Stem Cell for Blood Cancers

Phase 1 & 2
Waitlist Available
Led By Amanda Olson
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at day 30 post msc infusion
Awards & highlights

Study Summary

This trial will test whether it is feasible to use cord blood-derived mesenchymal stem cells (MSCs) to treat patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection. If it is successful, a larger trial will be conducted to compare the effect of MSCs with standard of care in these patients.

Eligible Conditions
  • Blood Cancers
  • Coronavirus Disease
  • COVID-19
  • COVID-19 Infection
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at day 30 post msc infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and at day 30 post msc infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of composite serious adverse events (Phase I)
Patients alive with grade 3 or 4 infusional toxicity (Phase II)
Patients alive without grade 3, 4 infusional toxicity (Phase II)
+1 more
Secondary outcome measures
Clinical parameters (Phase I)
Hospitalization stay (Phase I)
Incidence of infusion-related adverse events (Phase I)
+9 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Pilot study (mesenchymal stem cells)Experimental Treatment1 Intervention
Patients receive MSCs IV over 1-2 hours on day 1. Patients may receive a second infusion of MSCs within 7 days after the first infusion per physician discretion.
Group II: Phase II Arm I (mesenchymal stem cells)Experimental Treatment1 Intervention
Patients receive MSCs as in the Pilot study.
Group III: Phase II Arm II (standard of care)Active Control1 Intervention
Patients receive standard of care.

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,966 Previous Clinical Trials
1,804,711 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,654 Previous Clinical Trials
40,933,083 Total Patients Enrolled
1 Trials studying Blood Cancers
70 Patients Enrolled for Blood Cancers
Amanda OlsonPrincipal InvestigatorM.D. Anderson Cancer Center
4 Previous Clinical Trials
185 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor currently enrolling participants?

"According to the details provided on clinicaltrials.gov, this medical trial is no longer looking for patients as it was last updated in April of 2022; however, there are 5,543 other studies searching for participants at this moment."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome
2020. "Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04565665.
All > Ards
~15 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top